Tue.Feb 06, 2024

article thumbnail

Diabetes Can Serve as Traumatic Stressor for Adolescents, Young Adults

Drug Topics

A new study found that over a quarter of participants with type 1 daiebets exhibited clinically relevant levels of posttraumatic stress symptoms related to a diabetes event that they experienced.

201
201
article thumbnail

Black Women Experiencing Racism in 3 Categories Have Increased Risk of Coronary Heart Disease

Pharmacy Times

The investigators found that perceived racism in everyday life was not associated with a higher risk of coronary heart disease—only racism in the 3 specific categories.

149
149
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Supreme Court to weigh whether Covid misinformation is protected speech

STAT

WASHINGTON — As social media sites were flooded with misleading posts about vaccine safety, mask effectiveness, Covid-19’s origins and federal shutdowns, Biden officials urged platforms to pull down posts, delete accounts, and amplify correct information. Now the Supreme Court could decide whether the government violated Americans’ First Amendment rights with those actions — and dictate a new era for what role, if any, officials can play in combating misinformation on

Vaccines 145
article thumbnail

Negative Childhood Experiences Could Impact Cardiovascular Health in Adulthood

Pharmacy Times

In a study, more than 28% of participants met an ideal cardiovascular health score at the beginning of the study, with only 16% having ideal cardiovascular health at the 20-year mark.

131
131
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Opinion: Aduhelm was a mess — and it could happen again

STAT

Last week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer’s disease. Its decision, the company explained, is not a response to new data about the drug’s safety or efficacy, but instead “a reprioritization of resources.” Simply put, it wasn’t about science or medicine.

FDA 145
article thumbnail

Centene boosts guidance amid 'stronger than expected' marketplace enrollment

Fierce Healthcare

Centene posted $45 million in profit for the fourth quarter of 2023, with its profitability for the full year growing notably compared to 2022. | Centene posted $45 million in profit for the fourth quarter of 2023, with its profitability for the full year growing notably compared to 2022.

133
133

More Trending

article thumbnail

CMS Announces Cell and Gene Therapy Access Model Will Focus on Sickle Cell Disease

Pharmacy Times

The model was designed to help improve health outcomes, improve access to care, and lower costs for gene therapy.

149
149
article thumbnail

STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys

STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away. MorphoSys will not fare as well from the breakup.

143
143
article thumbnail

SAMHSA's final rule makes COVID-era flexibilities permanent for opioid treatment programs

Fierce Healthcare

Several COVID-era flexibilities relied upon by opioid treatment programs and their hundreds of thousands of patients will become permanent later this year, the Substance Abuse and Mental Healt | The final rule allows some providers to prescribe medication for opioid use disorder like buprenorphine via telehealth without an initial in-person exam. It also allows them to dispense unsupervised, take-home doses of methadone to relatively stable patients.

122
122
article thumbnail

STAT+: Colombia proceeds with plans to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT

The Colombian government has taken a significant step toward issuing a compulsory license for a widely used HIV treatment, the latest instance in which cash-strapped governments battle with the pharmaceutical industry over the cost of medicines. The government issued a notice last week inviting companies to indicate whether they would be willing to supply a generic version of dolutegravir, which is made by ViiV Healthcare, a company that specializes in HIV treatments and is largely controlled by

136
136
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Study Reveals Socioeconomic Disparity in Alcohol-Related IHD Mortality Risk

Drug Topics

Light-to-moderate alcohol consumption offers more protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status, potentially due to unequal access to health care.

98
article thumbnail

Opinion: The Philips CPAP nightmare exposes shortcomings in medical device regulation

STAT

Millions of Americans’ bedtime routine includes wearing a mask attached to a respiratory machine that pushes air into their lungs, supporting their breathing during sleep. These airway pressure machines, known as CPAP or BiPAP depending on their design, are sophisticated medical devices that have been used for decades by patients with sleep disorders like obstructive sleep apnea.

FDA 135
article thumbnail

Breathing Pattern of Longer Exhales Can Relieve Symptoms of Long COVID

Pharmacy Times

This breathing pattern is called resonant breathing and has been shown to improve heart rate variability.

149
149
article thumbnail

STAT+: House panel passes key PBM reform for sliver of commercial market

STAT

WASHINGTON — A House panel passed a bipartisan bill to ban drug middlemen from charging fees based on drug list prices — the first in Congress’ raft of PBM reform efforts that would actually ban the practice in at least some of the employer-sponsored insurance market. The bill, by Rep. Mariannette Miller-Meeks (R-Iowa), would only allow PBMs to charge a flat service fee, separating those fees from list prices.

Insurance 117
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Alternative therapies are needed to combat the impending threat of AMR

Pharmaceutical Technology

The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.

135
135
article thumbnail

STAT+: Why Eli Lilly’s earnings didn’t quite live up to the hype

STAT

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself. It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight-loss drug, sold under the brand names Mounjaro and Zepbound.

112
112
article thumbnail

AstraZeneca brings its cell therapy ambitions to Maryland with $300M plant investment, 150 planned hires

Fierce Pharma

Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. | AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs.

125
125
article thumbnail

CDC and social media: The new misinformation war

STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. In the age of misinformation, what can the government really do?

Hospitals 112
article thumbnail

A clearer harmony and attractiveness for EU Clinical Trials Regulation

pharmaphorum

For the latest episode of the pharmaphorum podcast, web editor Nicole Raleigh sat down with Chris Bamford, director of clinical trial regulatory management at IQVIA, and Shirley Rutter, associate director and strategic quality lead of global quality management at IQVIA Biotech.

115
115
article thumbnail

STAT+: Medicare threatens to pull funding from HCA’s embattled Mission Hospital

STAT

Five years after investor-owned HCA Healthcare took over an esteemed nonprofit hospital in North Carolina, Medicare is threatening to cut off payment for any services it provides seniors. The rare and dramatic move follows a Medicare revelation that patient safety is in “immediate jeopardy” at Mission Hospital in Asheville. That designation is the most severe the agency can hand out.

Hospitals 110
article thumbnail

Cedars-Sinai mental health app launches on Apple Vision Pro

pharmaphorum

Right after the official launch of the new Apple Vision Pro mixed reality headset, Cedars-Sinai has launched a generative artificial intelligence (genAI) app that will use the technology to provide mental health support for patients.

115
115
article thumbnail

Already rolling in diabetes and obesity, Eli Lilly touts tirzepatide's midstage MASH win

Fierce Pharma

In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.< | Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease with a massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect.

FDA 118
article thumbnail

Changing Faces: Pharma and biotech hires from January 2024

pharmaphorum

Stay updated with the latest news on hiring trends in the pharmaceutical and biotech industries. Learn about the companies and professionals making waves in the field from January 2024 in a new instalment of Changing Faces.

111
111
article thumbnail

New HRSA actions take aim at organ transplantation system

Fierce Healthcare

Following up on a federal law passed in September to increase competition among organ transplant contractors, the Health Resources and Services Administration (HRSA) is issuing requests for proposa | The Biden administration continues to break up the contract bidding process for organ procurements under new guidelines released Tuesday.

111
111
article thumbnail

Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab

Pharmacy Times

The company seeks the approval for both the intravenous and subcutaneous administration routes.

FDA 145
article thumbnail

The Correlation Between a New York State Law Repeal and Vaccine Coverage in Schools

Pharmaceutical Commerce

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

Vaccines 110
article thumbnail

How to identify the signs of anxiety and depression

The Checkup by Singlecare

Comorbidity | Compare symptoms | Depression symptoms | Anxiety symptoms | Overlapping symptoms | When to see a doctor | Treatment | Bottom line 50 million Americans—that’s 1 in 5 people in the country—have a mental health condition like anxiety or depression. While these conditions are very common, it’s easy for those experiencing mental health challenges to feel isolated and alone.

Vaccines 110
article thumbnail

How to ensure brand planning success for 2024

pharmaphorum

Daniel Kohlstaedt, managing director at PurpleLeaf Strategy, discusses how new technologies can help pharmaceutical leaders plan for success during their upcoming brand planning cycle.

109
109
article thumbnail

STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more

STAT

Top of the morning to you, and a fine one it is. Clear blue skies and rays of sunshine are enveloping the Pharmalot campus, where the official mascots are busy waking the neighbors and assorted other creatures are moseying about. As for us, we are immersed in the usual routine, which starts with firing up the coffee kettle and brewing cups of stimulation.

Insurance 104
article thumbnail

Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gains

Fierce Pharma

Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP | Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity.

115
115
article thumbnail

Medable's enhanced electronic consent making patients feel more human and less like study subjects

Outsourcing Pharma

Results from a new research project have been announced by technology provider Medable on the enhanced electronic informed consent (elC) in clinical trials.

114
114
article thumbnail

Vertex still knows how to do what it does best

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a close read of the latest blockbuster deal, a look at Novartis’ multibillion-dollar gamble, and a reminder of what Vertex Pharmaceuticals does well.

103
103
article thumbnail

Myavana embarks on experimental partnership with Ulta Beauty

Drug Store News

Myavana and Ulta Beauty have partnered on a Virtual Hair Analysis tool that helps guests understand their hair type and offers personalized product recommendations.

111
111
article thumbnail

Healthcare Dealmakers—General Catalyst's health system bid; Cigna's Medicare sell-off and more

Fierce Healthcare

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. | Missouri's $10 billion health system merger, Cardinal Health's $1.2 billion specialty care play and more merger and acquisition news from January.

105
105